TP53 and myelodysplastic syndrome: The significance of biallelic TP53 status was limited to MDS < 5% of blasts and not extended to those with higher blast cell percentages; MDS-EB1 and -EB2 with VAF > 10% had comparable survival; MDS EB-1 and EB-2 with VAF < 10% and CK had a poor survival compared to those without CK and comparable to that observed for MDS EB-1 or EB-2 with VAF > 10% [19].